3 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
December 31, | ||||||||
2023 | 2022 | |||||||
(in thousands) | ||||||||
Beginning balance of unrecognized tax benefits | $ | 8,176 | $ | 7,821 | ||||
Gross increases based on tax positions related to current year | 391 | 355 | ||||||
Gross increases based on tax positions related to prior years | 97 | — | ||||||
Ending balance of unrecognized tax benefits | $ | 8,664 | $ | 8,176 |
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
December 31, | ||||||||
2023 | 2022 | |||||||
(in thousands) | ||||||||
Compensation and benefits | $ | 10,011 | $ | 8,400 | ||||
Accrued research and development services ($3.1 million and nil due to related party in 2023 and 2022, respectively) | 5,004 | 889 | ||||||
Professional services | 787 | 1,187 | ||||||
Accrued clinical trial and preclinical costs | 4,705 | 652 | ||||||
Other | 750 | 408 | ||||||
Total accrued liabilities | $ | 21,257 | $ | 11,536 |
- Prev
- 1
- Next